Buy Like Buffett

The Moat Index

NovoCure Limited

NVCR · Healthcare · $1.8B mkt cap · FY2025 filings · No moat ·

Doesn't clear the bar

36/ 100
No moat

The four filters

Pricing power87

Median gross margin 74.8% over 10y, stable.

Returns on capital0

Median ROIC -22.7%, above the 9% hurdle in 0% of years.

Balance-sheet safety28

Net debt/EBITDA n/ax, interest coverage -7x.

Capital discipline24

Owner earnings trend unclear, share count growing (dilution).

Margin of safety

Above valueOn sale
No price data
Owner earnings (normalized)
—
Est. intrinsic value / share
—
Recent price
$15.92
Discount to value
No price data

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

14 years of fundamentals

The business, in plain English

NovoCure Limited booked $655.4M of revenue in FY2025 in the Healthcare sector and kept 74.5% of it as gross profit — a high-margin business by that measure. After every other cost, −20.8% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $10.4M (FY2013) to $655.4M (FY2025) — about 41.3% a year compounded over 12 years.

It earned −27.5% on invested capital in FY2025, with a median of −25.1% across 12 filed years. The Returns on Capital filter above scores it 0/100.

The balance sheet carried $195.0M of total debt in FY2025. Balance-Sheet Safety scores it 28/100.

The share count rose 737.5% between FY2014 and FY2025 — existing owners have been diluted over the record. Capital Discipline scores it 24/100.

Put together: Pricing Power is the strongest of the four filters (87/100) and Returns on Capital the weakest (0/100), which is how NVCR lands at 36/100 — a None moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2012–FY2025 · 14 fiscal years, normalized from NVCR’s SEC filings

RevenueSales, as filed$655.4M FY2025
$0$250M$500M2012201720222025
Gross marginRevenue kept after cost of goods74.5% FY2025
0%50%2012201720222025
Return on invested capitalOperating profit on the capital employed−27.5% FY2025
−100%0%2012201720222025
Owner earningsCash an owner could take out−$136.2M FY2025
−$200M−$100M$02012201720222025

Gaps in a line mean that item isn’t in NVCR’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Moat Score history

3 logged readings since Jul 17, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale36.4 / 100
0406080100WideNarrowShallowNo moatJul 17, 2026

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — NVCR has read No moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#285 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #283SCNX Scienture Holdings, Inc.36.5No moat
  2. #284LQDA LIQUIDIA CORPORATION36.5No moat
  3. #286FOSL Fossil Group, Inc.36.3No moat
  4. #287NVNO enVVeno Medical Corporation36.3No moat

Compare NVCR with its nearest peers →All Healthcare companies on the Index →

Common questions about NVCR

Does NovoCure Limited have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores NovoCure Limited (NVCR) 36.4 out of 100 — below the Shallow-moat bar, so no moat. The four filters behind that score (each 0–100): pricing power 87, returns on capital 0, balance-sheet safety 28, capital discipline 24.
How has NVCR's Moat Score changed over time?
The record logs 3 readings since Jul 17, 2026; the latest reads 36.4 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.
Embed this score on your site

One iframe, no script. The badge shows NVCR’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/NVCR"
  width="340" height="150" style="border:0"
  title="NVCR Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell NVCR. See the disclaimer.

NovoCure Limited (NVCR) Moat Score — The Moat Index · Buy Like Buffett